Hangzhou and Shanghai, China, May 12, 2026 — Degron Therapeutics (“Degron”), a clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines targeting previously undruggable or insufficiently drugged proteins, today announced that it has entered into a joint development collaboration agreement with MSD R&D (China) Co., Ltd. (“MSD”) to jointly advance the clinical development of molecular glue candidates in oncology.

Founded in 2021 by ShanghaiTech University professor and company co-founder Yong Cang, Ph.D., Degron Therapeutics built a de novo molecular glue degrader discovery platform, GlueXplorer^®. The company has created more than 10,000 structurally differentiated MGD compounds across more than 150 novel non-IMiDs cores, combined with multiple complementary screening and validation approaches. The platform has enabled Degron to build a pipeline of programs targeting important disease-causing proteins that have historically been inaccessible to conventional small-molecule drugs.

In addition to advancing its internal pipeline, Degron continues to partner with leading pharmaceutical and biotechnology companies to expand MGD R&D across multiple therapeutic areas, including its ongoing collaboration with Takeda.

“We are very pleased to enter into this collaboration with MSD to advance the clinical development of Degron’s novel molecular glue degrader candidates in oncology,” said Lily Zou, Ph.D., co-founder and CEO of Degron Therapeutics. “This partnership further validates the scientific strength and clinical potential of our innovative programs. By leveraging MSD’s deep expertise and leadership in oncology and clinical development, we look forward to accelerating the advancement of breakthrough therapies and furthering our mission to improve outcomes for patients worldwide.”

As a key innovative initiative of MSD global R&D, MSD R&D China Innovation Collaboration Center (MCICC) was officially established in 2024. It is dedicated to building an open, agile, and efficient innovation collaboration platform that focuses on high-potential projects during the early stages of R&D. By applying MSD’s global scientific resources with the strengths of China’s local innovation ecosystem, MCICC aims to harness more China-originated innovations to save and improve lives and benefit patients worldwide.

“In an increasingly open and collaborative biopharmaceutical ecosystem, we are eager to collaborate with local biopharmaceutical innovators to apply MSD’s established global R&D capabilities,” said Dr. Eliav Barr, Chief Medical Officer, MSD Research and Development. “By working together, we can advance innovation and accelerate clinical development with a focus on, and addressing unmet medical needs and creating value for patients both in China and worldwide.”

About Degron Therapeutics

Degron Therapeutics is a clinical-stage biotechnology company leveraging its molecular glue-based targeted protein degradation drug discovery platform to develop novel medicines and advance human health. The company's unique GlueXplorer^® platform encompasses a rapidly expanding IP-protected compound library and screening systems to develop a new class of small-molecule medicines that target important disease targets, including those previously undruggable. Degron has advanced its own first-in-class molecular glue degrader program into clinical development, with IND clearances in both the United States and China. The company's pipeline comprises a growing number of programs across oncology, inflammation, metabolic disorders, and rare diseases. Degron is headquartered in Shanghai, with offices in Hangzhou and San Diego. For more information, please visit www.degrontx.com.

About MSD R&D (China) Co., Ltd.

MSD China R&D Center is headquartered in Beijing, with research branches in Shanghai, Guangzhou, Chengdu, and Wuhan. The focused areas include oncology, vaccines, anti-infectives, cardiovascular and metabolic diseases, respiratory diseases, immunology, neuroscience, and ophthalmology. The oncology research programs cover more than 20 types of cancer, including several types that are highly prevalent in China. Since its establishment in China, MSD has introduced over 80 innovative drugs, vaccines, new indications and companion diagnostics to the Chinese market, continuously addressing the clinical needs of local patients.